uniQure (NASDAQ:QURE) CEO Sells $952,063.12 in Stock

uniQure N.V. (NASDAQ:QURE) CEO Matthew Kapusta sold 21,082 shares of the business’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $45.16, for a total value of $952,063.12. Following the completion of the sale, the chief executive officer owned 519,227 shares in the company, valued at $23,448,291.32. This represents a 3.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

uniQure Trading Up 0.1%

uniQure stock traded up $0.05 during midday trading on Tuesday, reaching $41.41. 2,218,137 shares of the stock traded hands, compared to its average volume of 2,726,536. The company has a 50-day simple moving average of $31.01 and a two-hundred day simple moving average of $24.02. uniQure N.V. has a 12-month low of $8.73 and a 12-month high of $71.50. The firm has a market cap of $2.61 billion, a PE ratio of -11.90 and a beta of 0.90. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33.

uniQure (NASDAQ:QURE) last posted its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.03. The business had revenue of $3.56 million during the quarter, compared to analyst estimates of $5.21 million. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. Research analysts expect that uniQure N.V. will post -3.63 earnings per share for the current fiscal year.

Institutional Investors Weigh In On uniQure

Several large investors have recently modified their holdings of QURE. Torren Management LLC acquired a new stake in shares of uniQure during the fourth quarter worth $28,000. IFP Advisors Inc purchased a new position in uniQure during the 4th quarter worth $48,000. Smartleaf Asset Management LLC acquired a new stake in shares of uniQure in the 4th quarter worth $48,000. CIBC Private Wealth Group LLC purchased a new stake in shares of uniQure in the third quarter valued at about $50,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of uniQure by 42.7% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,027 shares of the biotechnology company’s stock valued at $72,000 after acquiring an additional 906 shares in the last quarter. 78.83% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

QURE has been the subject of several research reports. HC Wainwright boosted their price target on shares of uniQure from $50.00 to $80.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Weiss Ratings reissued a “sell (e+)” rating on shares of uniQure in a research note on Friday, June 26th. Wall Street Zen upgraded uniQure from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. Stifel Nicolaus set a $28.00 target price on shares of uniQure in a research note on Tuesday, May 5th. Finally, Wells Fargo & Company raised shares of uniQure from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $15.00 to $60.00 in a report on Monday, March 9th. Twelve research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $64.17.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.